# FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

> **NCT00578201** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 80 (actual)

## Conditions studied

- Esophageal Cancer Stage III

## Interventions

- **DRUG:** radiochemotherapy,combination Cetuximab-FOLFOX

## Key facts

- **NCT ID:** NCT00578201
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2011-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578201, "FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00578201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*